Ece Bayram1, David G Coughlin1, Irene Litvan1. 1. Parkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego, La Jolla, California, USA.
Abstract
BACKGROUND: Lewy body (LB) dementias have limited clinical diagnostic accuracy because of frequent copathologies contributing to clinical heterogeneity. Although sex differences in clinical prevalence and frequency of pure LB pathology were shown, differences for clinicopathological correlations are less known. OBJECTIVE: The aim of this study was to determine sex differences for clinical associations of Alzheimer's disease (AD) copathology in those with LB pathology. METHODS: Data were from National Alzheimer's Coordinating Center for 223 women and 468 men with limbic or neocortical LB, separated into two groups as those with high likelihood and low/intermediate likelihood for LB clinical phenotype based on pathology. Clinical associations of sex and interaction of sex and pathology for the clinical phenotype were analyzed. RESULTS: More severe AD copathology was associated with worse cognitive decline and lower likelihood of LB disease clinical phenotype. Women with more severe AD copathology and tau had worse cognitive decline and higher likelihood of AD clinical phenotype than men. Men with more severe AD copathology had lower likelihood of LB clinical phenotype than women. Interaction of sex and pathology was more pronounced in those aged between 70 and 80 years. CONCLUSIONS: AD copathology reduces the likelihood of LB clinical phenotype for both women and men; however, men may be at higher risk for LB disease underdiagnosis and women at higher risk for dementia. The use of both LB and AD biomarkers, even when LB or AD pathology is not clinically expected, is necessary for the accurate clinical diagnosis of both LB diseases and AD.
BACKGROUND: Lewy body (LB) dementias have limited clinical diagnostic accuracy because of frequent copathologies contributing to clinical heterogeneity. Although sex differences in clinical prevalence and frequency of pure LB pathology were shown, differences for clinicopathological correlations are less known. OBJECTIVE: The aim of this study was to determine sex differences for clinical associations of Alzheimer's disease (AD) copathology in those with LB pathology. METHODS: Data were from National Alzheimer's Coordinating Center for 223 women and 468 men with limbic or neocortical LB, separated into two groups as those with high likelihood and low/intermediate likelihood for LB clinical phenotype based on pathology. Clinical associations of sex and interaction of sex and pathology for the clinical phenotype were analyzed. RESULTS: More severe AD copathology was associated with worse cognitive decline and lower likelihood of LB disease clinical phenotype. Women with more severe AD copathology and tau had worse cognitive decline and higher likelihood of AD clinical phenotype than men. Men with more severe AD copathology had lower likelihood of LB clinical phenotype than women. Interaction of sex and pathology was more pronounced in those aged between 70 and 80 years. CONCLUSIONS: AD copathology reduces the likelihood of LB clinical phenotype for both women and men; however, men may be at higher risk for LB disease underdiagnosis and women at higher risk for dementia. The use of both LB and AD biomarkers, even when LB or AD pathology is not clinically expected, is necessary for the accurate clinical diagnosis of both LB diseases and AD.
Authors: Thomas J Montine; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; John Q Trojanowski; Harry V Vinters; Bradley T Hyman Journal: Acta Neuropathol Date: 2011-11-20 Impact factor: 17.088
Authors: Kai Sin Chin; Nawaf Yassi; Leonid Churilov; Colin Louis Masters; Rosie Watson Journal: Parkinsonism Relat Disord Date: 2020-09-23 Impact factor: 4.891
Authors: Tresa M Roebuck-Spencer; Tannahill Glen; Antonio E Puente; Robert L Denney; Ronald M Ruff; Gayle Hostetter; Kevin J Bianchini Journal: Arch Clin Neuropsychol Date: 2017-06-01 Impact factor: 2.813
Authors: Peter T Nelson; Frederick A Schmitt; Gregory A Jicha; Richard J Kryscio; Erin L Abner; Charles D Smith; Linda J Van Eldik; William R Markesbery Journal: J Neurol Date: 2010-06-20 Impact factor: 4.849
Authors: Rodolfo Savica; Brandon R Grossardt; James H Bower; Bradley F Boeve; J Eric Ahlskog; Walter A Rocca Journal: JAMA Neurol Date: 2013-11 Impact factor: 18.302
Authors: Salvatore Spina; Renaud La Joie; Cathrine Petersen; Amber L Nolan; Deion Cuevas; Celica Cosme; Mackenzie Hepker; Ji-Hye Hwang; Zachary A Miller; Eric J Huang; Anna M Karydas; Harli Grant; Adam L Boxer; Maria Luisa Gorno-Tempini; Howard J Rosen; Joel H Kramer; Bruce L Miller; William W Seeley; Gil D Rabinovici; Lea T Grinberg Journal: Brain Date: 2021-03-09 Impact factor: 13.501
Authors: E E Wolters; M van de Beek; R Ossenkoppele; S S V Golla; S C J Verfaillie; E M Coomans; T Timmers; D Visser; H Tuncel; F Barkhof; R Boellaard; A D Windhorst; W M van der Flier; Ph Scheltens; A W Lemstra; B N M van Berckel Journal: Neuroimage Clin Date: 2020-11-19 Impact factor: 4.881